Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of LCI699 in Renal Impairment
NCT02399202Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of osilodrostat in Cushing's syndrome (3 arms), sponsored by Novartis. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration at 72 hours, Area Under the Concentration-Time Curve from Time Zero to Infinity at 72 hours and 2 more. Started Nov 2015; status: completed.
02
Drugs
osilodrostat
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT02399202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399202.